Document is current
Any future updates will be listed below
-
Authors
Touilloux, Brice https://orcid.org/0009-0008-0924-6775
Casutt, Alessio https://orcid.org/0000-0003-3824-9613
Truong, Minh Khoa https://orcid.org/0000-0002-1177-0815
Bongard, Cédric https://orcid.org/0009-0009-7707-7106
Lechartier, Benoit https://orcid.org/0000-0001-5932-8164
Marques-Vidal, Pedro https://orcid.org/0000-0002-4548-8500
Vollenweider, Peter https://orcid.org/0000-0002-0765-896X
Vaucher, Julien https://orcid.org/0000-0002-3230-3693
von Garnier, Christophe Von https://orcid.org/0000-0003-3585-9176
-
Funding
Funding for this research was provided by:
University of Lausanne
- License Information
-
More Information
Article History
Received: 17 April 2025
Accepted: 24 June 2025
First Online: 30 September 2025
Declarations
:
: The CoLaus|PsyCoLaus baseline protocol received initial ethical approval from the Institutional Ethics Committee of the University of Lausanne, which subsequently became the Ethics Commission of the Canton of Vaud (), under reference numbers 16/03; 134-03, 134-05bis, and 134-05-2to5 addenda 1to4. Subsequent approvals were obtained for each follow-up: the first follow-up (33/09; 239/09), the second (26/14; 239/09 addendum 2), and the third (PB_2018-00040; 239/09 addenda 3to4). In 2021, a renewed approval for the cohort and the fourth follow-up was granted under PB_2018-0038; 239/09.
: Not Applicable. This manuscript does not contain any information or images that could allow identification of the study participants.
: Christophe Von Garnier had grants and contracts with OM Pharma. Christophe Von Garnier received consultation fees from AstraZeneca, GSK, Boehringer Ingelheim and OM Pharma. Christophe Von Garnier received Payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from AstraZeneca, GSK and OM pharma. Pedro Marques-Vidal participated as member of the scientific Advisory Board for Santé Publique France. The other authors declared no conflicts of interests.
